Comparative Pharmacology
Head-to-head clinical analysis: CHOLETEC versus OMNIPAQUE 12.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLETEC versus OMNIPAQUE 12.
CHOLETEC vs OMNIPAQUE 12
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Choletec is a technetium-99m labeled iminodiacetic acid derivative used for hepatobiliary scintigraphy. It is taken up by hepatocytes via organic anion transporting polypeptides and excreted into bile canaliculi via multidrug resistance-associated protein 2, allowing visualization of the biliary system.
Radiopaque agent that attenuates X-rays, providing contrast in imaging. Iodine atoms absorb X-rays, enhancing visualization of blood vessels and tissues.
1 gram intravenously every 8 hours; maximum 3 g/day.
Adult dose: 12 g iodine (e.g., 200 mL of Omnipaque 12) administered intravenously, intra-arterially, or into body cavities. Typical contrast study dose: 1-2 mL/kg (max 150 mL) for CT; 40-60 mL for angiographic procedures.
None Documented
None Documented
Terminal elimination half-life is approximately 16–24 hours; clinically, once-daily dosing achieves steady-state after 5–7 days, allowing for pharmacological effects on bile acid composition.
1-2 hours (normal renal function); prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min)
Primarily biliary (approx. 50–70% as unchanged drug and metabolites) with fecal elimination; renal excretion is minimal (<5% unchanged).
Renal: >95% unchanged; biliary/fecal: <5%
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent